Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus PK after conversion from Prograf to Advagraf in stable pediatric transplant recipients
2024-513546-11-00Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2024
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tacrolimus in solid organ transplant rejection (SOTR), sponsored by Astellas Pharma. Primary endpoint: Steady-state tacrolimus systemic exposure. Started Jun 2024; status: completed.
02
Drugs
tacrolimus
03
Conditions
solid organ transplant rejection (SOTR)
Beyond the preview
Go deeper on 2024-513546-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513546-11-00.